Sodium-glucose co-transporter 2 inhibitors: A new path for heart failure treatment

Jaewon Oh, Seung Hyun Lee, Chan Joo Lee, Seok Min Kang

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

Results from cardiovascular outcome trials (CVOT) with 5 different sodium-glucose co-transporter 2 inhibitors (SGLT2i; empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, sotagliflozin), initially developed for their glucose-lowering effect by blocking tubular glucose reabsorption in kidney, have been shown to decrease the risk of heart failure hospitalization (HFH) across a range of patients with and without atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). Following these CVOT results, SGLT2i (dapagliflozin, empagliflozin, sotagliflozin) also were reported to reduce HFH and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of existence or absence of T2DM. Ongoing studies have been conducted to evaluate the clinical benefit of SGLT2i (empagliflozin, dapagliflozin) in patients with heart failure with preserved ejection fraction (HFpEF). Although SGLT2i brought us to the entrance of a new era for prevention of HF incidence and worsening of HF, the search for pivotal mechanism of SGLT2i to improve our pharmacological armamentarium should continue in order to protect every HF patient from fatal progression of HF disease. In this review, we summarized the updated clinical evidences on SGLT2i (rather than basic and translational evidence) for reduction of HF risk in T2DM patients and favorable clinical outcomes in both HFrEF and HFpEF patients.

Original languageEnglish
Article number0070
JournalKorean Circulation Journal
Volume51
Issue number6
DOIs
Publication statusPublished - 2021 Jun

Bibliographical note

Funding Information:
medium, provided the original work is properlyuse, distribution, and reproduction in any Results from cardiovascular outcome trials (CVOT) with 5 different sodium-glucose co-cited. transporter 2 inhibitors (SGLT2i; empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, sotagliflozin), initially developed for their glucose-lowering effect by blocking tubular glucose reabsorption in kidney, have been shown to decrease the risk of heart failure hospitalization (HFH) across a range of patients with and without atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). Following these CVOT results, SGLT2i (dapagliflozin, empagliflozin, sotagliflozin) also were reported to reduce HFH and Funding cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), Provisional This work was partly supported by the Basic regardless of existence or absence of T2DM. Ongoing studies have been conducted to Science Research Program through the evaluate the clinical benefit of SGLT2i (empagliflozin, dapagliflozin) in patients with heart National Research Foundation of Korea (NRF) failure with preserved ejection fraction (HFpEF). Although SGLT2i brought us to the entrance funded by the Ministry of Education (NRF- of a new era for prevention of HF incidence and worsening of HF, the search for pivotal by a grant from the Korea Food Research2020R1I1A1A01074368) and partly supported mechanism of SGLT2i to improve our pharmacological armamentarium should continue Institute funded by the Ministry of Science, ICT in order to protect every HF patient from fatal progression of HF disease. In this review, we & Future Planning (E0210400). summarized the updated clinical evidences on SGLT2i (rather than basic and translational evidence) for reduction of HF risk in T2DM patients and favorable clinical outcomes in both HFrEF and HFpEF patients.

Publisher Copyright:
© 2021. The Korean Society of Cardiology.

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Sodium-glucose co-transporter 2 inhibitors: A new path for heart failure treatment'. Together they form a unique fingerprint.

Cite this